Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Emixustat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Emixustat SCHEMBL2204159 | 1.00 | PARP10 (0.46) | PARP10 | |
| SCHEMBL2205395 | 1.00 | PARP10 (0.46) | PARP10 | |
| Emixustat SCHEMBL29366946 | 1.00 | PARP10 (0.46) | PARP10 | |
| SCHEMBL29818966 | 1.00 | PARP10 (0.46) | PARP10 | |
| Emixustat SCHEMBL2202461 | 1.00 | PARP10 (0.46) | PARP10 | |
| SCHEMBL15150981 | 1.00 | PARP10 (0.46) | PARP10 | |
| SCHEMBL29818746 | 1.00 | PARP10 (0.46) | PARP10 | |
| Emixustat SCHEMBL4568946 | 1.00 | PARP10 (0.46) | PARP10 | |
| SCHEMBL2202614 | 1.00 | PARP10 (0.46) | PARP10 | |
| SCHEMBL4572122 | 1.00 | PARP10 (0.46) | PARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 294 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250188025-A1 | COMPOSITIONS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS | UNIV CASE WESTERN RESERVE (US) | 2025-06-12 | — | — | US | claimed |
| US-12060318-B2 | Compositions and methods for the delivery of nucleic acids | CASE WESTERN RESERVE UNIVERSITY (US) | 2024-08-13 | — | — | US | claimed |
| US-20230338580-A1 | PLASMID VECTORS AND NANOPARTICLES FOR TREATING OCULAR DISORDERS | UNIV CASE WESTERN RESERVE (US) | 2023-10-26 | — | — | US | claimed |
| US-20230270700-A1 | PHARMACOLOGY OF VISUAL CYCLE MODULATORS | ACUCELA INC. | 2023-08-31 | — | — | US | claimed |
| EP-4196140-A1 | PLASMID VECTORS AND NANOPARTICLES FOR TREATING OCULAR DISORDERS | CASE WESTERN RESERVE UNIVERSITY (US) | 2023-06-21 | — | — | EP | claimed |
| EP-4000610-A1 | PHARMACOLOGY OF VISUAL CYCLE MODULATORS | Acucela Inc. (US) | 2022-05-25 | — | — | EP | claimed |
| WO-2022036318-A1 | PLASMID VECTORS AND NANOPARTICLES FOR TREATING OCULAR DISORDERS | CASE WESTERN RESERVE UNIVERSITY (US) | 2022-02-17 | — | — | WO | claimed |
| EP-2448569-B1 | PHARMACOLOGY OF VISUAL CYCLE MODULATORS | ACUCELA INC (US) | 2021-10-27 | — | — | EP | claimed |
| US-20200354315-A1 | COMPOSITIONS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS | CASE WESTERN RESERVE UNIVERSITY | 2020-11-12 | — | — | US | claimed |
| US-10792374-B2 | Compositions and methods for the delivery of nucleic acids | CASE WESTERN RESERVE UNIVERSITY (US) | 2020-10-06 | — | — | US | claimed |
| US-9957224-B2 | Methods for the treatment of diabetic retinopathy and other ophthalmic diseases | ACUCELA INC (US) | 2018-05-01 | — | — | US | claimed |
| EP-3210966-A1 | ALKOXYPHENYLPROPYLAMINES FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION | Acucela, Inc. (US) | 2017-08-30 | — | — | EP | claimed |
| US-9737496-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2017-08-22 | — | — | US | claimed |
| US-20170049722-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2017-02-23 | — | — | US | claimed |
| US-8993807-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2015-03-31 | — | — | US | claimed |
| US-20120122938-A1 | Alkoxy Compounds for Disease Treatment | ACUCELA INC. (US) | 2012-05-17 | — | — | US | claimed |
| EP-2448569-A2 | PHARMACOLOGY OF VISUAL CYCLE MODULATORS | Acucela, Inc. (US) | 2012-05-09 | — | — | EP | claimed |
| US-7982071-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2011-07-19 | — | — | US | claimed |
| WO-2011003103-A2 | PHARMACOLOGY OF VISUAL CYCLE MODULATORS | ACUCELA, INC. (US) | 2011-01-06 | — | — | WO | claimed |
| US-20110003895-A1 | Pharmacology of Visual Cycle Modulators | ACUCELA, INC. (US) | 2011-01-06 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003895-A1 | Pharmacology of Visual Cycle Modulators | NR2E3, ALDH1A2, RARB | PARP10 1642/4885 |
| US-20200354315-A1 | COMPOSITIONS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS | RBP4, RBP1, RARB | PARP10 1651/4885 |
| US-10792374-B2 | Compositions and methods for the delivery of nucleic acids | HNRNPH3, HNRNPR, HNRNPAB | PARP10 1482/4885 |
| US-20120122938-A1 | Alkoxy Compounds for Disease Treatment | ALDH1A2, CLN6, AGER | PARP10 1814/4885 |
| US-20230338580-A1 | PLASMID VECTORS AND NANOPARTICLES FOR TREATING OCULAR DISORDERS | GRK1, GRK7, NR2E3 | PARP10 1675/4885 |
| US-20250188025-A1 | COMPOSITIONS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS | RBP4, RBP1, RARB | PARP10 1651/4885 |
| US-20230270700-A1 | PHARMACOLOGY OF VISUAL CYCLE MODULATORS | NR2E3, ALDH1A2, RARB | PARP10 1642/4885 |
| US-20170049722-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ALDH1A2, CLN6, AGER | PARP10 1814/4885 |
| US-12060318-B2 | Compositions and methods for the delivery of nucleic acids | RBP4, RBP1, RARB | PARP10 1651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.